

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Qyuns Therapeutics Co., Ltd.
江蘇荃信生物醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2509)

POLL RESULTS OF THE ANNUAL GENERAL MEETING
HELD ON MAY 31, 2024

According to the notice dated April 29, 2024 (the “**Notice**”), the supplemental notice dated May 14, 2024 (the “**Supplemental Notice**”) and the announcement dated May 16, 2024 (the “**Announcement**”) of the annual general meeting (the “**AGM**”) of Qyuns Therapeutics Co., Ltd. (the “**Company**”), the AGM of the Company was held at North Conference Room, 2nd Floor, Building 1, No. 907 Yaocheng Avenue, Taizhou City, Jiangsu Province, the PRC on Friday, May 31, 2024 at 2:00 p.m. Unless otherwise defined, capitalised terms in this announcement shall have the same meaning as given to them in the Notice, the Supplemental Notice and the Announcement.

The total number of the issued shares of the Company as at the date of the AGM was 222,071,600 shares, of which 17,322,400 shares were unlisted shares and 204,749,200 shares were H shares. Accordingly, the total number of shares entitling the holders to attend and vote for or against any of the proposed resolutions at the AGM was 222,071,600 shares.

There were no shares entitling the shareholders to attend and abstain from voting in favour of any of the proposed resolutions at the AGM as set out in Rule 13.40 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) (the “**Listing Rules**”). None of the shareholders of the Company has stated his or her intention in the Circular to vote against or abstain from voting on any resolutions at the AGM. There were no shareholders of the Company that were required under the Listing Rules to abstain from voting on any of the proposed resolutions at the AGM.

The number of shareholders and proxies of shareholders attending the AGM in person was 4. Shareholders and proxies of shareholders who attended the AGM held a total of 131,833,601 shares with voting rights, representing approximately 59.37% of the total number of shares with voting rights.

The holding of the AGM was in compliance with the requirements of the Company Law of the PRC (《中華人民共和國公司法》) and the Articles of Association of the Company.

Tricor Investor Services Limited, the Company’s H share registrar, acted as the scrutineer for the vote-taking at the AGM.

The following Directors of the Company attended the AGM: Mr. Qiu Jiwan, Mr. Wu Yiliang and Mr. Lin Weidong as executive Directors; Mr. Yu Xi, Mr. Wu Zhiqiang and Dr. Xue Mingyu as non-executive Directors; and Dr. Zou Zhongmei, Dr. Ling Jianqun and Mr. Fung Che Wai, Anthony as independent non-executive Directors.

VOTING RESULTS OF THE AGM

At the AGM of the Company held on May 31, 2024, all the proposed resolutions as set out in the Notice, the Supplemental Notice and the Announcement were taken by poll. The poll results are as follows:

Ordinary Resolutions		Number of Votes (%)		
		For	Against	Abstain
1.	To consider and approve the report of the board of directors (the “ Board ”) of the Company for the year ended December 31, 2023.	131,833,601 (100.00%)	0 (0.00%)	0 (0.00%)
2.	To consider and approve the report of the board of supervisors of the Company for the year ended December 31, 2023.	131,833,601 (100.00%)	0 (0.00%)	0 (0.00%)
3.	To consider and approve the annual report of the Group which include the audited consolidated financial statements and the reports of the auditor of the Company for the year ended December 31, 2023.	131,103,601 (99.45%)	0 (0.00%)	730,000 (0.55%)
4.	To consider and approve the proposed profit distribution plan of the Company for the year ended December 31, 2023.	131,103,601 (99.45%)	0 (0.00%)	730,000 (0.55%)
5.	To consider and approve the remuneration scheme for directors and supervisors of the Company for the year ending December 31, 2024.	131,103,601 (99.45%)	0 (0.00%)	730,000 (0.55%)
6.	To consider and approve the engagement of KPMG as the auditor of the Company to hold office until the conclusion of the next annual general meeting of the Company and to authorise the Board to determine their remuneration.	131,103,601 (99.45%)	0 (0.00%)	730,000 (0.55%)
* As more than half of the votes were cast in favour of each of the resolutions numbered 1 to 6, all resolutions were duly passed as ordinary resolutions.				

Special Resolutions		Number of Votes (%)		
		For	Against	Abstain
7.	To consider and approve the provision of a guarantee by the Company to its subsidiary for a credit line of not more than RMB300 million.	131,103,601 (99.45%)	0 (0.00%)	730,000 (0.55%)
8.	To consider and approve the proposed granting of the general mandate to the Board to issue H shares.	131,103,601 (99.45%)	0 (0.00%)	730,000 (0.55%)
9.	To consider and approve the provision of a guarantee by the Company to its subsidiary for a guarantee line of not more than RMB100 million in aggregate.	131,103,601 (99.45%)	0 (0.00%)	730,000 (0.55%)
* As more than two-thirds of the votes were cast in favour of the resolutions numbered 7 to 9, all resolutions were duly passed as special resolutions.				

By Order of the Board
Qyuns Therapeutics Co., Ltd.
Qiu Jiwan
Chairman of the Board and Executive Director

Hong Kong, May 31, 2024

As at the date of this announcement, the board of directors of the Company comprises Mr. Qiu Jiwan as chairman and executive Director, Mr. Wu Yiliang and Mr. Lin Weidong as executive Directors, Mr. Yu Xi, Mr. Wu Zhiqiang and Dr. Xue Mingyu as non-executive Directors, and Dr. Zou Zhongmei, Dr. Ling Jianqun and Mr. Fung Che Wai, Anthony as independent non-executive Directors.